- Pressemitteilung BoxID 524667
Sartorius Stedim Biotech Recognized as Innovations Honoree for FlexMoSys
Pharmaceutical Manufacturing Magazine distinguishes SSB for modular and mobile cleanroom system
The FlexMoSys module has been developed by G-Con Manufacturing and is equipped, distributed and installed by Sartorius Stedim Biotech. The system combines SSB's broad, single-use and reusable product portfolio and G-Con's novel cleanroom pods and thus offers a totally integrated production process platform. It enables GMP-compliant cleanroom space to be created that is faster, more flexible and significantly less expensive to set up and operate than a conventional, large purpose-built facility. Standard pods of the FlexMoSys cleanroom system come equipped with plumbing, data, video and voice interface, as well as provide many other features and benefits. In addition, the system can be conveniently tailored to a customer's specific needs as the customer can choose from an entire suite of fully integrated bioprocessing equipment like SSB's FlexAct solutions. The FlexMoSys pods can be easily moved due to installed air bearings underneath each pod. This is important when modular unit operations must be placed in a different sequence or a pod has to be decontaminated.
"FlexMoSys unlocks the full potential of customizable, cost-effective unit operations. It gives the biopharmaceutical industry a considerable head start in manufacturing biologics, such as vaccines," said Maik Jornitz, Senior Vice President of Marketing for Bioprocess Solutions at Sartorius Stedim Biotech. "Furthermore, it reflects the innovation potential of what we offer in cooperation with G-Con Manufacturing. The breakthrough revolution in biomanufacturing processes has now become a reality and has only just begun," he stated.
Über Sartorius AG
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions."
Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs more than 2,800 people, and in 2011 earned sales revenue of 477.3 million euros.
Diese Pressemitteilungen könnten Sie auch interessieren
Die Saison startet ...innerhalb des erfolgreichen Ems-Dollart-Region-Projektes zur Etablierung der Zuckerrübe als Biogassubstrat sind in der Region zwei Feldtage...
Fachtagung 2013 des Gissel Instituts: Aktuelle Themen rund um die Fleischverarbeitung stehen im Blickpunkt
Kaum eine Veranstaltung dürfte geeigneter sein, sich in Sachen Fleisch und Fleischwaren auf den neuesten Stand zu bringen, als die regelmäßige Fachtagung des renommierten...
BioTek kündigt stolz die erste Kombination aus Multi-Detektions-Reader mit Hybrid-Technologie und Imaging-System an - den Cytation™3 Multi-Detektions-Reader für...